Takeshi Takahashi
Directeur/Membre du Conseil chez Pathalys Pharma, Inc.
Profil
Takeshi Takahashi is currently the Director at Pathalys Pharma, Inc. He previously worked as an Independent Director at Mineralys Therapeutics, Inc. from 2020 to 2023.
He also held the position of Co-Chief Operating Officer & Manager-Technology II at Tsugami Corp.
Mr. Takahashi completed his undergraduate degree at Waseda University and holds an MBA from Kellogg School of Management.
Postes actifs de Takeshi Takahashi
| Sociétés | Poste | Début |
|---|---|---|
Pathalys Pharma, Inc.
 Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | Directeur/Membre du Conseil | - |
Anciens postes connus de Takeshi Takahashi
| Sociétés | Poste | Fin |
|---|---|---|
| MINERALYS THERAPEUTICS, INC. | Directeur/Membre du Conseil | 12/09/2023 |
| TSUGAMI CORPORATION | Directeur des opérations | - |
Formation de Takeshi Takahashi
| Waseda University | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MINERALYS THERAPEUTICS, INC. | Health Technology |
| TSUGAMI CORPORATION | Producer Manufacturing |
| Entreprise privées | 1 |
|---|---|
Pathalys Pharma, Inc.
Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | Health Technology |
